Human papillomavirus (HPV) vaccination is the most effective biomedical intervention for HPV infections. HPV vaccination rate among sexually active young adults is largely unknown.
Methods
Patients aged 18–26 years, who attended the Rhode Island Sexually Transmitted Infections Clinic between 2013–2018, were included in the study. We extracted demographics, behavioral characteristics, and HPV vaccination status from electronic medical records. Exploratory logistic regressions were conducted to identify factors associated with vaccination status.
Results
Among 2729 eligible individuals, the median age was 23 years (interquartile range: 22–25). Only 8.1% of males and 24.8% of females received at least one dose of HPV vaccine. Females were 144% (crude odds ratio [cOR]: 2.44, 95% confidence interval [CI]: 2.03, 2.94) more likely to receive at least one dose of HPV vaccine than males. Being Black/African American (B/AA) or Hispanic/Latino (H/L) was associated with a 21% (cOR: 0.79, 95% CI: 0.62, 1.00) and 34% (cOR: 0.66, 95% CI: 0.53, 0.81) decrease in the odds of vaccination, respectively.
Conclusions
HPV vaccination rate was low among sexually active young adults. Gender and racial/ethnic disparities existed in HPV vaccination. Interventions are needed to promote HPV vaccination among sexually active young adults, especially B/AA and H/L communities.
SatterwhiteCLTorroneEMeitesE, et al.Sexually transmitted infections among US women and men: prevalence and incidence estimates. Sex Transmitted Diseases2013; 40(3): 187–193. DOI: 10.1097/OLQ.0b013e318286bb53.
2.
PurcellDWJohnsonCHLanskyA, et al.Estimating the population size of men who have sex with men in the United States to obtain HIV and syphilis rates. Open AIDS Journal2012; 6: 98–107. DOI: 10.2174/1874613601206010098.
3.
WeaverBA. Epidemiology and natural history of genital human papillomavirus infection. J Am Osteopathic Assoc2006; 106(3 Suppl 1): S2–S8.
4.
ChessonHWEkwuemeDUSaraiyaM, et al.Estimates of the annual direct medical costs of the prevention and treatment of disease associated with human papillomavirus in the United States. Vaccine2012; 30(42): 6016–6019. DOI: 10.1016/j.vaccine.2012.07.056.
5.
JemalASimardEPDorellC, et al.Annual report to the nation on the status of cancer, 1975-2009, featuring the burden and trends in human papillomavirus(HPV)-associated cancers and HPV vaccination coverage levels. J Natl Cancer Inst2013; 105(3): 175–201. DOI: 10.1093/jnci/djs491.
6.
PatelHWagnerMSinghalP, et al.Systematic review of the incidence and prevalence of genital warts. BMC Infectious Diseases2013; 13: 39. DOI: 10.1186/1471-2334-13-39.
7.
GiulianoARTortolero-LunaGFerrerE, et al.Epidemiology of human papillomavirus infection in men, cancers other than cervical and benign conditions. Vaccine2008; 26(Suppl 100 10): K17–K28. DOI: 10.1016/j.vaccine.2008.06.021.
HarperDMFrancoELWheelerC, et al.Efficacy of a bivalent L1 virus-like particle vaccine in prevention of infection with human papillomavirus types 16 and 18 in young women: a randomised controlled trial. Lancet (London, England)2004; 364(9447): 1757–1765. DOI: 10.1016/s0140-6736(04)17398-4.
10.
HarperDMFrancoELWheelerCM, et al.Sustained efficacy up to 4.5 years of a bivalent L1 virus-like particle vaccine against human papillomavirus types 16 and 18: follow-up from a randomised control trial. Lancet (London, England)2006; 367(9518): 1247–1255. DOI: 10.1016/s0140-6736(06)68439-0.
11.
VillaLLAultKAGiulianoAR, et al.Immunologic responses following administration of a vaccine targeting human papillomavirus types 6, 11, 16, and 18. Vaccine2006; 24(27–28): 5571–5583. DOI: 10.1016/j.vaccine.2006.04.068.
12.
MarkowitzLEHaririSLinC, et al.Reduction in human papillomavirus (HPV) prevalence among young women following HPV vaccine introduction in the United States, national health and nutrition examination surveys, 2003–2010. J Infectious Diseases2013; 208(3): 385–393. DOI: 10.1093/infdis/jit192.
13.
LukácsAMátéZFarkasN, et al.The quadrivalent HPV vaccine is protective against genital warts: a meta-analysis. BMC Public Health2020; 20(1): 691. DOI: 10.1186/s12889-020-08753-y.
14.
McClungNMGarganoJWBennettNM, et al.Trends in human papillomavirus vaccine types 16 and 18 in cervical precancers, 2008–2014. Cancer Epidemiology, Biomarkers Prevention: A Publication Am Assoc Cancer Res Cosponsored by Am Soc Prev Oncol2019; 28(3): 602–609. DOI: 10.1158/1055-9965.Epi-18-0885.
15.
SerranoBBrotonsMBoschFX, et al.Epidemiology and burden of HPV-related disease. Best Practice Research Clin Obstetrics Gynaecology2018; 47: 14–26. DOI: 10.1016/j.bpobgyn.2017.08.006.
16.
DunneEFUngerERSternbergM, et al.Prevalence of HPV infection among females in the United States. Jama2007; 297(8): 813–819. DOI: 10.1001/jama.297.8.813.
17.
KingEMMesherDSonnenbergP, et al.HPV16 and HPV18 seropositivity and DNA detection among men who have sex with men: a cross-sectional study conducted in a sexual health clinic in London. Sex Transmitted Diseases2020; 97: 1–5.
18.
KingEMGilsonRBeddowsS, et al.Human papillomavirus DNA in men who have sex with men: type-specific prevalence, risk factors and implications for vaccination strategies. Br J Cancer2015; 112(9): 1585–1593. DOI: 10.1038/bjc.2015.90.
19.
MolinaJMCapitantCSpireB, et al.On-demand preexposure prophylaxis in men at high risk for HIV-1 infection. New Engl Journal Medicine2015; 373(23): 2237–2246. DOI: 10.1056/NEJMoa1506273.
20.
AgénorMA-OPeitzmeierSMGordonAR, et al.Sexual orientation identity disparities in human papillomavirus vaccination initiation and completion among young adult US women and men. Cancer Causes Control2016; 27(10): 1187–1196.
21.
CharltonBMReisnerSLAgénorM, et al.Sexual orientation disparities in human papillomavirus vaccination in a longitudinal cohort of U.S. males and females. LGBT Health2017; 4(3): 202–209. DOI: 10.1089/lgbt.2016.0103.
22.
SavoyM. ACIP releases 2016 adult immunization recommendations. Am Family Physician2016; 93(4): 323–326.
23.
GerendMAMadkinsKPhillipsG2nd, et al.Predictors of human papillomavirus vaccination among young men who have sex with men. Sex Transmitted Diseases2016; 43(3): 185–191. DOI: 10.1097/olq.0000000000000408.
24.
MeitesELlataEHaririS, et al.HPV vaccine implementation in STD clinics--STD surveillance network. Sex Transmitted Diseases2012; 39(1): 32–34. DOI: 10.1097/OLQ.0b013e3182315584.
25.
WilsonRBrownDRBootheMA, et al.Knowledge and acceptability of the HPV vaccine among ethnically diverse black women. J Immigr Minor Health2013; 15(4): 747–757.
26.
Nationalstate. local area vaccination coverage among adolescents aged 13–17 years --- United States, 2009. MMWR Morbidity Mortality Weekly Report2010; 59(32): 1018–1023.
27.
LuqueJSRaychowdhurySFWeaverM. Health care provider challenges for reaching hispanic immigrants with HPV vaccination in rural Georgia. Rural Remote Health2012; 12(2): 1975.
28.
McQuillanGMKruszon-MoranDMarkowitzLE, et al.Prevalence of HPV in adults aged 18-69: United States, 2011–2014. NCHS Data Brief2017; 280: 1–8.
29.
PatelRRHarrisonLCPatelVV, et al.HIV pre-exposure prophylaxis programs incorporating social applications can reach at-risk men who have sex with men for successful linkage to care in Missouri, USA. J Assoc Nurses AIDS Care2017; 28: 428–430. DOI: 10.1016/j.jana.2017.01.003.
30.
ChanPAFlaniganTP. Effective HIV prevention interventions and the need for rapid mobilization to address hiv outbreaks among at-risk populations. J Infectious Diseases2017; 215: 1491–1492. DOI: 10.1093/infdis/jix101.
